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Pauli OhukainenAbstract
During the past 100 years, several theories explaining human atherosclerosis have been postulated and tested.
More than anything else, experimental and observational evidence has supported a very strong causal role for
dyslipidemia. This has been established as the current paradigm in both biomedical research as well as public
health policies. Recently, a novel hypothesis for the etiology of atherosclerosis was presented. The purpose of this
commentary is to critically evaluate its validity.
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In a recent article published in Lipids in Health and
Disease [1], a novel hypothesis for the pathogenesis of
atherosclerosis is presented. The “mevalonate hypothesis”
suggests that stimulation of the mevalonate pathway in
endothelial cells and subsequent production of free radi-
cals would be the true cause of both ox-LDL and there-
fore, also atherosclerosis. Science advances through the
constant re-evaluation of existing data but whenever a
long-standing scientific consensus is challenged, one is
compelled to look very closely at why and how. In this
case, the novel hypothesis seems interesting but also
unnecessary and critically flawed. The purpose of this
commentary is to examine some of the issues of the
“mevalonate hypothesis”.Discussion
In the article, two main points are raised as being prob-
lematic for the prevailing cholesterol theory. One is that
ox-LDL is the only thing that really matters in athero-
genesis and that its absolute amounts are determined
primarily by the concentration of local oxygen radicals.
The author suggests that since the amount of these radi-
cals must be low due to their high reactivity, the con-
centration of LDL itself is irrelevant to the formation of
ox-LDL. This premise is flawed in three ways. First, it
doesn’t recognize that the widely accepted initiating
factor in the pathogenesis of atherosclerosis is actually
the retention of apoB-containing particles within theCorrespondence: pauli.ohukainen@oulu.fi
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reproduction in any medium, provided the orsubendothelial proteoglycan [2]. This seems to be the
rate-limiting step because if the apoB protein is modified
so that it doesn’t bind to proteoglycan, even a marked in-
crease in LDL-C does not promote significant atherogen-
esis [3]. Secondly, there seems to be several factors besides
oxygen radicals that contribute to the oxidation of LDL
such as enzymatic reactions [4]. And thirdly, it has been
demonstrated that macrophages are able to take up LDL
particles even in their unmodified form [5].
The second point raised against the current paradigm
is based on lipid-lowering intervention trials. Indeed
there have been some negative results but the totality of
evidence very strongly suggests that there is substantial
benefit in LDL lowering and that this can be seen even
when systematically pooling together results from differ-
ent medications, diets, hormone therapies and even sur-
gical treatments [6]. The author cites some negative
statin trials done in highly specific patient populations
as examples of the drugs’ universal ineffectiveness. This
argument also ignores the totality of evidence that shows
that there is indeed benefit from statin therapy and that
it is proportional to both the total risk of the patient as
well as the absolute reduction in LDL [7]. In addition to
these intervention trials, one must not ignore the
supporting evidence from low-risk populations [8] and
people with lifetime exposure to low LDL due to genetic
reasons [9].
All scientific hypotheses can be either validated or fal-
sified by experimental data. If the “mevalonate hypothesis”
is true, elevated serum cholesterol is merely a biomarker
for increased risk of atherosclerotic disease and not a
causal factor. This is contradicted by various experimentaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cholesterolemic diet and/or genetic modifications have all
been shown to be directly atherogenic. It also seems that
the proposed hypothesis is based on the premise that in-
creased cholesterol production in endothelial cells could
contribute to serum cholesterol levels. While it is true that
accumulation of endogenous cholesterol is toxic to the
cell and therefore requires a reverse transport system,
this cholesterol efflux from endothelial cells would be
reflected only in the HDL fraction of serum cholesterol
[10]. There is no evidence that endothelial cells could
produce apoB-containing lipoproteins.
Conclusions
Increased NADPH-oxygenase activity and free radicals
probably do have a role in the complex disease that is
atherosclerosis. However it seems that there is no real
reason to consider a replacement hypothesis for the cur-
rent paradigm. Also, despite providing food for thought,
the suggested “mevalonate hypothesis” is currently un-
able to overthrow a hundred years’ worth of progressive
research.
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